Risankizumab, guselkumab, and ustekinumab were associated with the lowest risk for progression from psoriasis to psoriatic arthritis.

Content by Public Service Company of Oklahoma. Learn how the Public Service Company of Oklahoma keeps the lights on for customers through every possible weather outcome.

Mar 28, 2026-- Takeda ( TSE:4502/NYSE:TAK ) today announced new data from the two pivotal Phase 3 studies of zasocitinib (TAK-279 ...

A Pasco County pastor and former deputy was arrested on multiple charges of lewd and lascivious behavior and molestation involving minors, according to the sheriff's office.

A New Port Richey pastor and former deputy was charged by the Pasco Sheriff's Office with lewd and lascivious behavior ...

Pearson plc is leveraging AI-driven efficiency and digital transformation to drive sustained margin expansion and free cash flow growth. Learn more about PSO stock here.

The European Medicines Agency has endorsed expanded use of Sotyktu for psoriatic arthritis, recommending approval after clinical trials showed improvement in joint symptoms.

HealthDay News — Once-daily oral zasocitinib (TAK-279), an oral tyrosine kinase 2 (TYK2) inhibitor, provides a durable response in adults with moderate-to-severe plaque psoriasis (PsO), according to a ...

When a Tulsa man couldn't get PSO to clean up a mess left by its powerline tree trimmers, 2 News Oklahoma's Cathy Tatom listened and got results.

Adding tirzepatide to ixekizumab significantly improved primary and key secondary outcomes ...

Alumis is preparing to file its oral TYK2 inhibitor envudeucitinib as a treatment for psoriasis later this year, after a pair of positive phase 3 trials. The South San Francisco biotech said ...

One-year Phase 3 data for ICOTYDE to be presented at AAD 2026 demonstrate lasting skin clearance and a favorable safety ...